Theravance Biopharma Inc. (NASDAQ:TBPH) shares dropped 9.2% on Wednesday . The company traded as low as $24.26 and last traded at $24.75, with a volume of 321,365 shares trading hands. The stock had previously closed at $27.26.

Several research firms have recently commented on TBPH. Leerink Swann began coverage on Theravance Biopharma in a report on Thursday, May 12th. They set an “outperform” rating and a $26.00 price target on the stock. Zacks Investment Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 19th. Guggenheim began coverage on Theravance Biopharma in a report on Monday, June 20th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Bank of America Corp. lowered Theravance Biopharma from a “neutral” rating to an “underperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $24.75.

The firm’s market capitalization is $1.18 billion. The stock has a 50 day moving average price of $23.35 and a 200 day moving average price of $20.15.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.14. The company earned $18.40 million during the quarter, compared to analysts’ expectations of $18.69 million. On average, analysts predict that Theravance Biopharma Inc. will post ($4.30) earnings per share for the current fiscal year.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.